Lin xiaoyan

Lin xiaoyan

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
JYJing Yang
Jing Yang
LWLizhu Weng
Lizhu Weng
ZCZhikui Chen
Zhikui Chen
HCHongfu Cai
Hongfu Cai
LXLin xiaoyan
Lin xiaoyan
MLMaobai Liu
Maobai Liu
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: The incidence of cancer pain increases in discharged patients because of discontinued standard treatments and reductions in medication compliance. Motivated by the need for better pain management in discharged patients, we developed a mobile phone application (Pain Guard) for providing continuous treatment information and feedback to discharged patients suffering from pain. Objective: To design, construct, and test Pain Guard in patients managing cancer pain, and evaluate the total remission rate of pain and the improvement in quality of life (QoL), in order to improve pain management for patients who receive treatment both within and outside the hospital. Methods: This randomized controlled double-arm study involved 58 patients with cancer pain symptoms. Participants were randomly assigned to a group receiving care through the Pain Guard app or to a control group who received only traditional pharmaceutical care. In a pre-test, participants were rated using a baseline cancer-pain assessment and QoL evaluation. During treatment, the consumption levels of analgesic drugs were recorded every week. After a 4-week study period, another round of cancer-pain assessment and QoL evaluation was conducted. The system’s usability, feasibility, compliance, and satisfaction were also assessed. Our primary outcome was remission rate of pain, and secondary outcomes were compliance with medication, improvements in QoL, frequency of breakthrough cancer pain (BTcP), incidence of adverse reactions, and satisfaction of patients. Results: All participants (58 patients) successfully completed the study. There were no significant differences in baseline pain score or baseline QoL scores between groups (P>0.10). At the end of the study, the rate of pain remission in the trial group was significantly higher than that in the control group (P<.01). The frequency of BTcP in the trial group was considerably lower than that in the control group (P<.01). The rate of medication compliance in the trial group was considerably higher than that in the control group (P<.01). Improvements in QoL scores in the trial group were also significantly higher than those in the control group (P<.01). The incidence of adverse reactions in the trial group (7/31) was much lower than that in the control group (12/27). The 31 participants in the trial group completed a satisfaction survey regarding Pain Guard: 23 (74%) indicated that they were satisfied with receiving pharmaceutical care by Pain Guard, 8 (26%) indicated that they were somewhat satisfied, 2 (6%) indicated neutral feelings, 1 (3%) indicated that they were somewhat dissatisfied, and no participants indicated that they were very dissatisfied. Conclusions: Pain Guard was effective for the management of pain in discharged patients with cancer pain, and its operability was effective and easily accepted by patients. Clinical Trial: identifier: ChiCTR1800016066

1 October 2021 in International Immunopharmacology
Verified
Journal Article
Open access
HCHao Chen
Hao Chen
TJTao Jiang
Tao Jiang
FLFangyu Lin
Fangyu Lin
HGHongdan Guan
Hongdan Guan
JZJianwei Zheng
Jianwei Zheng
LXLin xiaoyan
Lin xiaoyan
To explore the effect of programmed death 1 (PD-1) inhibitor combined with apatinib on immune regulation and efficacy of the combined therapy in mice bearing gastric cancer (MBGC), and to provide a research basis for enhancing the benefit of immunotherapy in advanced gastric cancer (AGC). MBGC were divided into normal saline group (group NS), apatinib group (group A), PD-1 inhibitors group (group B) and PD-1 inhibitors combined with apatinib group (group C). Tumor inhibition rates were calculated. Cytokine levels and expression of immune cells and molecules were detected, and the pathological manifestations of tumor tissues were observed. Group C had the smallest tumor volume (115.17 ± 16.08 mm3) with a tumor inhibition rate of 89.4% ± 0.69%, significantly increased levels of CD4+T and CD8+T cells in tumor tissues (P < 0.01), the down-regulated proportion of myeloid-derived suppressor cells (MDSCs) (P < 0.01), and levels of PD-1 of CD8+T cells (PD-1+CD8+T) (P < 0.01). There was no difference in the levels of PD-1+CD8+T, CD4+T cells, and MDSCs between groups B and C. Besides, combination therapy increased the levels of interleukin-2 (IL-2), interferon-gamma (IFN-γ), and tumor necrosis factor-ɑ (TNF-ɑ) in tumor tissue and serum. We also found that the anti-angiogenic effect of apatinib increased programmed death ligand-1 (PD-L1) levels, down-regulated vascular endothelial growth factor receptor 2 (VEGFR-2) levels, and induced an increase in the extent of tumor tissue necrosis. PD-1 inhibitors in combination with apatinib may help improve treatment outcomes and increase survival benefits in patients with AGC.

24 October 2022 in Sustainability
Verified
Journal Article
Open access
PDF file
XLXIANJIN LIN
XIANJIN LIN
LXLin xiaoyan
Lin xiaoyan
JZJun Zhang
Jun Zhang
QHQionge He
Qionge He
PYPengyu Yan
Pengyu Yan
China’s goal of reaching peak carbon by 2030 and carbon neutrality by 2060 has been a popular research topic in recent years. Carbon peaking and carbon neutrality goals are solemn commitments made by the Chinese government to the international community. As a national ecological civilization demonstration area, Fujian province has incorporated peak carbon and carbon neutrality into its overall ecological construction plans. This paper uses the scalable stochastic environmental impact assessment model STIRPAT to quantitatively analyze the relationship between carbon emission intensity and economy, population, energy intensity, energy structure, and industrial structure in Fujian Province from 2001 to 2020, and it uses a Markov transition matrix to predict the ratio of energy structure in the next four years. On the basis of the above-mentioned research, combined with the provincial ecological planning outlined in the 14th Five-Year Plan of Fujian Province, three development modes (i.e., the general mode, the energy-saving mode, and the energy consumption mode) are proposed. Finally, according to the model, this paper predicts that the carbon intensity goal of 2025 can be achieved under the general and energy saving modes, while the carbon intensity goal cannot be reached under the energy consumption mode.

18 October 2018 in JMIR Preprints
Verified
Preprint
Open access
JYJing Yang
Jing Yang
LWLizhu Weng
Lizhu Weng
ZCZhikui Chen
Zhikui Chen
HCHongfu Cai
Hongfu Cai
LXLin xiaoyan
Lin xiaoyan
MLMaobai Liu
Maobai Liu
BACKGROUND The incidence of cancer pain increases in discharged patients because of discontinued standard treatments and reductions in medication adherence. Motivated by the need for better pain management in discharged patients, we developed a mobile phone app (Pain Guard) to provide continuous treatment information and feedback to discharged cancer patients suffering from pain. OBJECTIVE The aim was to design, construct, and test the Pain Guard app in patients managing cancer pain, evaluate the total remission rate of pain and the improvement in quality of life (QoL) to improve pain management for cancer pain patients, and assess patient acceptance of the app. METHODS This randomized controlled double-arm study involved 58 patients with cancer pain symptoms. Participants were randomly assigned to a group receiving care through the Pain Guard app (n=31) or to a control group (n=27) who received only traditional pharmaceutical care. In a pretest, participants were rated using a baseline cancer pain assessment and QoL evaluation. During treatment, the consumption levels of analgesic drugs were recorded every week. After a 4-week study period, another round of cancer pain assessment and QoL evaluation was conducted. The system’s usability, feasibility, app compliance, and satisfaction were also assessed. Our primary outcome was remission rate of pain, and secondary outcomes were medication adherence, improvements in QoL, frequency of breakthrough cancer pain (BTcP), incidence of adverse reactions, and satisfaction of patients. RESULTS All participants (N=58) successfully completed the study. There were no significant differences in baseline pain scores or baseline QoL scores between groups. At the end of the study, the rate of pain remission in the trial group was significantly higher than that in the control group (P<.001). The frequency of BTcP in the app group was considerably lower than that in the control group (P<.001). The rate of medication adherence in the trial group was considerably higher than that in the control group (P<.001). Improvements in global QoL scores in the trial group were also significantly higher than those in the control group (P<.001). The incidence of adverse reactions in the trial group (7/31) was lower than that in the control group (12/27), especially constipation, with significant differences (P=.01). The 31 participants in the trial group completed a satisfaction survey regarding Pain Guard: 23 (74%) indicated that they were satisfied with receiving pharmaceutical care by Pain Guard, 5 (16%) indicated that they were somewhat satisfied, 2 (6%) indicated neutral feelings, and 1 (3%) indicated that they were somewhat dissatisfied; no participants indicated that they were very dissatisfied. CONCLUSIONS Pain Guard was effective for the management of pain in discharged patients with cancer pain, and its operability was effective and easily accepted by patients. CLINICALTRIAL Chinese Clinical Trials Registry ChiCTR1800016066; http://www.chictr.org.cn/showproj.aspx?proj=27153


19 June 2013
Verified
Book Chapter
Closed access
PDF file
LXLin xiaoyan
Lin xiaoyan